We are monitoring the impact of COVID-19 on Biologics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 10292
Share on
Share on

Global Biologics Market Size, Share, Trends, COVID-19 Impact and Growth Analysis Report – Segmented By Source, Product, Biologics Manufacturing Type, Disease Category and Region – Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 10292
Pages: 200

Biologics Market Size (2021 to 2026)

As per our analysis report, the global biologics market size was worth USD 269.1 billion in 2020 and is expected to exhibit an 8.1% CAGR from 2021 to 2026.

A biologic is a component derived from the living organism and is made up of living organisms, and these products are derived from humans, animals, and microorganisms using biotechnology. These products represent cutting-edge research and also enable the latest scientific discoveries. Such discoveries can be translated into novel therapies that provide new treatment options for patients. Key players in the market focus on collaborations and partnerships to commercialize biologics drugs and gain a competitive edge in the global market.

MARKET DRIVERS:

The growth of the global biologics market is majorly driven by the factors such as government initiatives, steps to develop innovative techniques, Y-O-Y growth in the incidence of chronic diseases, growing healthcare expenditure, and rising prevalence to promote excellent treatment procedures.

Increasing acceptability of innovative therapies and rising demand for biologic drugs with an increasing number of patent expiries are expected to favor the market's growth rate. Biologics have wide applications in the targeted therapies and help treat various medical conditions when treatments unavailable. Gene-based and cellular biologics are major elements in biomedical research, which is expected to act as a favorable sign to the growth rate of the market.

Additionally, the rising scale of pharmaceutical companies worldwide, growing initiatives of government organizations to spread awareness among people over the availability of different treatment procedures for the targeted diseases are further greatly influencing the growth rate of the market. Also, there is an increased efficacy for the oral products for various diseases such as Crohn’s and rheumatoid arthritis, pulling patients to adopt novel treatment procedures. This is enhancing the growth rate of the biologics market eventually. The rising geriatric population and increasing prominence to lower the cost of treatment procedures also impel the market demand. Also, people's preference for pills rather than injections is gearing up the growth rate of the market. Technological advancements are also expanding the growth rate of the market. For instance, Eli Lilly and Pfizer adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models more effectively in early drug discovery.

The launch of innovative therapies with the latest technologies is anticipated to set growth opportunities for the market. A reduction in the demand for small molecule drug R&D activities is expected to promote the demand of the biologics market in the near future.

MARKET RESTRAINTS:

Lack of proper knowledge over the utilization of biologics in the research centers and the complex regulatory structure by the government in approving the new products are some of the major factors hindering the growth rate of the global biologics market.

Additionally, long-term use of biologics leads to certain problems such as changes in blood pressure, gastrointestinal complications, breathing problems, and others that are slowly hampering the market’s demand. Supervise treatment procedures with biologics require advanced technologies. This is quietly to restrain the demand of the market. The dearth of skilled people in laboratories to analyze the outcome also limits the growth rate of the biologics market. The high cost for installation and maintenance of the devices in laboratories also impedes the demand of this market.

The manufacturing process of the biologics drugs is a little complex where that remains a big challenging factor for the biologics market to grow. Less turnover for clinical trials is declining the growth rate of the biologics market.

Impact of COVID-19 on the global biologics market:

COVID 19 pandemic has disrupted almost every sector in an unprecedented way. The novel coronavirus has been spreading at rapid speed since the WHO declared it as a pandemic. Most people infected by COVID 19 have mild symptoms such as cold, cough, fever, loss of smell or taste. It may yield severe heart failure symptoms, acute respiratory distress syndrome, and others for older people aged 65 to 70. The Biologics market has a declining growth rate in the initial months of 2020. The market was valued at USD 249 billion in 2019, dropping to USD 239 billion in 2020. The primary reason for the declined growth rate is to lock down restrictions and ban flights. As the treatment procedures using biologics are postponed or canceled, the market shares have reduced suddenly. The number of patients infected with the coronavirus and getting treatment with biologics is very less. This is a major factor for the biologics market to have a slow growth rate in 2020. By taking certain measures, all the activities were resumed in the hospitals and clinics. All the postponed treatment procedures were resumed in the last months of 2020, and the treatment procedures were using biologics.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Source, Product, Biologics Manufacturing Type, Disease Category and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

This research report on the global biologics market has been segmented and sub-segmented based on source, product, biologics manufacturing type, disease category, and region.

Biologics Market – By Source:  

  • Microbial
  • Mammalian
  • Others

A microbial source has dominated the source segment and is expected to grow at the highest rate. Scientists have found a wide variety of beneficial applications that can be derived from microbial source biologics. This reason is a major contributing factor in this sub-segment.

A mammalian source has second place in this segment and is expected to grow at a reasonable growth rate but less than the microbial sub-segment. More research is going on in this field by scientists, and soon this source will have the same market share as microbial.

Biologics Market – By Product:

Based on the product, the monoclonal antibodies have dominated the biologics market in terms of revenue. They are expected to have high growth due to their higher usage in different therapeutic areas. Monoclonal antibodies allow the targeting of unhealthy cells without harming healthy cells. These drugs are beneficial in cancer management, treatment of autoimmune diseases, including rheumatoid arthritis.

Vaccines are anticipated to witness the fastest growth in the coming years owing to usage as a preventative tool in infectious diseases. In the current time, when a world is suffering from a deadly virus, there is an immediate need for an effective virus, and the development of biologics will be a key to the development of vaccines.

Biologics Market – By Biologics Manufacturing:

  • Outsourced
  • In-house

Manufacturing is a part of the significant steps of biologics production and comprises a substantial share of the biologics market. It has two segments, 'Outsourced' and 'In-house.' Companies are opting to manufacture biologics in their plants, and thus, In-house is dominating the market. Companies are engaged in investing in their bioprocessing capabilities. The companies are investing more in their plants to increase their commercial manufacturing capacity. The rising population has forced the countries to be self-sustained, as in the world pandemic, and there might be problems in supply if dependent on others.

Biologics Market – By Disease Category:

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Oncology accounted for the largest share due to the rising incidence of cancer coupled and to cure. There is the presence of different R&D projects. These projects include gene therapies and antisense therapies for cancer eradication. The oncology also had the second-highest growth rate among all other sub-segments. The advantages of cancer therapy are a significant reason.

The infectious disease sub-segment has the second largest market share. The increase in the viral disease's negative impact has led to more investments in treating infectious diseases. It will soon take over the oncology sub-segment.

Immunological disorders, cardiovascular disorders, and hematological disorders have third, fourth and fifth places, respectively.

Biologics Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American biologics market had dominated the global biologics market concerning revenue generation due to significant established participants in this region. The North American region has the world's 80% research being done in healthcare biotechnology. Higher demand for the products for the treatment of diseases has increased the revenue share of this region.

Globally, the European biologics market was the second-largest regional market in 2020 and is expected to grow reasonably. The improvement of healthcare quality and the rise in disease cases have fuelled the growth in this region.

The Asia Pacific biologics market is expected to be at the fastest rate during the forecast period and is considered the most lucrative region for biologics in the global market. Large population and high expected population growth have led to more investments in this science, thus boosting the biologics market.

the Latin America Biologics market is estimated to be growing at a healthy CAGR during the forecast period. It is further expected to be driven by such factors as increased capital investment by major market players coupled with increased support and initiatives from governments of various countries around the world for the development and implementation of biologics.

The MEA biologics market size is expected to showcase a healthy growth rate during the forecast period. There is an increase in High Throughput Screening (HTS) technology in the Middle East and Africa for various drug development processes. The technology is used to identify threads to discover an inhibitor of Middle East Respiratory Syndrome (MERS). This factor is attributed to fuel the growth rate of the biologics market in the MEA region.

KEY MARKET PARTICIPANTS:

Johnson & Johnson (J&J), F Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly and Company, Merck & Co., and Pfizer Inc. are some of the dominating companies in the global biologics market.

SOME OF THE RECENT HAPPENINGS IN THIS MARKET:

  • In August 2019, National Centre for Research and Development had funded Euro 6.7 Billion to Wroclaw-based pure Biologics, a biotech startup, for its PureBike project. The project focussed on developing an immuno-oncological drug that is useful to treat triple-negative breast cancer (TNBC). 
  • In September 2019, BioCare Medical LLC, a leading provider of immunohistochemistry (IHC) instrumentation and reagents, announced the launch of p16INK4a, a new mouse monoclonal antibody. It is cost-effective and showing accurate results in the evaluation of cervical biopsies.
  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
        1. Secondary Research
        2. Primary Research
        3. Econometric Modelling
        4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Source
      1. Microbial
      2. Mammalian
      3. Others
    2. By Product
      1. Monoclonal Antibodies
      2. Vaccines
      3. Recombinant Proteins
      4. Antisense, RNAi, & Molecular Therapy
      5. Others
    3. By Biologics Manufacturing
      1. Outsourced
      2. In-house
    4. By Disease Category
      1. Oncology
      2. Infectious Diseases
      3. Immunological Disorders
      4. Cardiovascular Disorders
      5. Hematological Disorders
      6. Others
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. North America
      1. Introduction
      2. US
      3. Canada
    3. Europe
      1. Introduction
      2. UK
      3. France
      4. Spain
      5. Germany
      6. Italy
    4. Asia-Pacific
      1. Introduction
      2. India
      3. China
      4. Japan
      5. South Korea
      6. Australia
    5. Latin America
      1. Introduction
      2. Brazil
      3. Argentina
      4. Mexico
    6. Middle East & Africa
      1. Introduction
      2. Middle East
      3. Africa
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Johnson & Johnson (J&J)
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. F Hoffmann-La Roche
    3. Bristol-Myers Squibb
    4. GlaxoSmithKline
    5. AbbVie
    6. Amgen
    7. Sanofi
    8. Eli Lilly and Company
    9. Merck & Co.
    10. Pfizer
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

  • Segment-level analysis in terms of Source, Product, Biologics Manufacturing Type, Disease Category and Region along with market size forecasts and estimations to detect key areas of industry growth in detail

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis

  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

  1. Global Biologics Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  3. Global Microbial Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Mammalian Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  6. Global Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  7. Global Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  11. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  13. Global Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global In-house Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  16. Global Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  17. Global Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  18. Global Immunological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  19. Global Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  20. Global Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  21. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  22. North America Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  23. North America Microbial Market, By Region, From 2021 to 2026 (USD Billion)
  24. North America Mammalian Market, By Region, From 2021 to 2026 (USD Billion)
  25. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  26. North America Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  27. North America Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  30. North America Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  33. North America Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  34. North America In-house Market, By Region, From 2021 to 2026 (USD Billion)
  35. North America Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  36. North America Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  37. North America Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  38. North America Immunological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  39. North America Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  40. North America Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  41. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  42. United States Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  43. United States Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  44. United States Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  45. United States Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  46. Canada Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  47. Canada Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  48. Canada Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  49. Canada Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  50. Europe Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  51. Europe Microbial Market, By Region, From 2021 to 2026 (USD Billion)
  52. Europe Mammalian Market, By Region, From 2021 to 2026 (USD Billion)
  53. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  54. Europe Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  55. Europe Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  56. Europe Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  57. Europe Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  58. Europe Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  59. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  60. Europe Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  61. Europe Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  62. Europe In-house Market, By Region, From 2021 to 2026 (USD Billion)
  63. Europe Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  64. Europe Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  65. Europe Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  66. Europe Immunological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  67. Europe Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  68. Europe Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  69. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  70. U.K. Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  71. U.K. Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  72. U.K. Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  73. U.K. Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  74. Germany Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  75. Germany Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  76. Germany Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  77. Germany Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  78. France Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  79. France Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  80. France Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  81. France Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  82. Italy Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  83. Italy Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  84. Italy Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  85. Italy Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  86. Spain Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  87. Spain Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  88. Spain Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  89. Spain Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  90. Asia Pacific Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  91. Asia Pacific Microbial Market, By Region, From 2021 to 2026 (USD Billion)
  92. Asia Pacific Mammalian Market, By Region, From 2021 to 2026 (USD Billion)
  93. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  94. Asia Pacific Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  95. Asia Pacific Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  96. Asia Pacific Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  97. Asia Pacific Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  98. Asia Pacific Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  99. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  100. Asia Pacific Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  101. Asia Pacific Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  102. Asia Pacific In-house Market, By Region, From 2021 to 2026 (USD Billion)
  103. Asia Pacific Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  104. Asia Pacific Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  105. Asia Pacific Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  106. Asia Pacific Immunological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  107. Asia Pacific Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  108. Asia Pacific Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  109. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  110. Japan Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  111. Japan Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  112. Japan Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  113. Japan Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  114. China Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  115. China Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  116. China Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  117. China Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  118. India Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  119. India Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  120. India Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  121. India Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  122. Australia Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  123. Australia Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  124. Australia Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  125. Australia Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  126. South Korea Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  127. South Korea Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  128. South Korea Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  129. South Korea Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  130. Latin America Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  131. Latin America Microbial Market, By Region, From 2021 to 2026 (USD Billion)
  132. Latin America Mammalian Market, By Region, From 2021 to 2026 (USD Billion)
  133. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  134. Latin America Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  135. Latin America Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  136. Latin America Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  137. Latin America Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  138. Latin America Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  139. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  140. Latin America Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  141. Latin America Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  142. Latin America In-house Market, By Region, From 2021 to 2026 (USD Billion)
  143. Latin America Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  144. Latin America Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  145. Latin America Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  146. Latin America Immunological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  147. Latin America Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  148. Latin America Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  149. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  150. Brazil Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  151. Brazil Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  152. Brazil Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  153. Brazil Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  154. Argentina Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  155. Argentina Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  156. Argentina Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  157. Argentina Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  158. Mexico Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  159. Mexico Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  160. Mexico Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  161. Mexico Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  162. Rest of Latin America Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  163. Rest of Latin America Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  164. Rest of Latin America Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  165. Rest of Latin America Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  166. Middle East and Africa Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  167. Middle East and Africa Microbial Market, By Region, From 2021 to 2026 (USD Billion)
  168. Middle East and Africa Mammalian Market, By Region, From 2021 to 2026 (USD Billion)
  169. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  170. Middle East and Africa Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  171. Middle East and Africa Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Billion)
  172. Middle East and Africa Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  173. Middle East and Africa Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Billion)
  174. Middle East and Africa Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  175. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  176. Middle East and Africa Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  177. Middle East and Africa Outsourced Market, By Region, From 2021 to 2026 (USD Billion)
  178. Middle East and Africa In-house Market, By Region, From 2021 to 2026 (USD Billion)
  179. Middle East and Africa Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  180. Middle East and Africa Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  181. Middle East and Africa Infectious Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  182. Middle East and Africa Immunological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  183. Middle East and Africa Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  184. Middle East and Africa Hematological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  185. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  186. Middle East Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  187. Middle East Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  188. Middle East Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  189. Middle East Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)
  190. Africa Biologics Market, By Source, From 2021 to 2026 (USD Billion)
  191. Africa Biologics Market, By Product, From 2021 to 2026 (USD Billion)
  192. Africa Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Billion)
  193. Africa Biologics Market, By Disease Category, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4250

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample